Vemurafenib

Vemurafenib Reactions 1680, p331 - 2 Dec 2017 Acantholytic dyskeratotic acanthoma: case report A 62-year-old woman developed acantholytic dyskeratotic acanthoma (ADA) following the therapy with vemurafenib. The woman was diagnosed with melanoma when she was 59 years old. She had undergone surgery, followed by nivolumab therapy. However, the disease progressed and advanced to systemic metastasis. Hence, to treat the multiple metastasis, she started receiving therapy with vemurafenib 960 mg/day [route not stated]. After one month of vemurafenib initiation, she developed a keratotic papule on her right shoulder. A skin biopsy of the papule was performed, which ruled out the possibility of squamous cell carcinoma. Histologically, the lesion demonstrated mild papillomatous acanthosis and hyperkeratosis. Acantholysis and dyskeratosis with corp ronds and grains were noted. Therefore, the papule was diagnosed as ADA that developed due to the vemurafenib therapy [outcome not stated]. Author comment: "In conclusion, we experienced a case of vemurafenib-induced ADA." Komori T, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment. Journal of the European Academy of Dermatology and Venereology 31: e474-e475, No. 10, Oct 2017. Available from: URL: http:// doi.org/10.1111/jdv.14289 - Japan 803284154 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Vemurafenib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/vemurafenib-x69c7XkGNT
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39262-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p331 - 2 Dec 2017 Acantholytic dyskeratotic acanthoma: case report A 62-year-old woman developed acantholytic dyskeratotic acanthoma (ADA) following the therapy with vemurafenib. The woman was diagnosed with melanoma when she was 59 years old. She had undergone surgery, followed by nivolumab therapy. However, the disease progressed and advanced to systemic metastasis. Hence, to treat the multiple metastasis, she started receiving therapy with vemurafenib 960 mg/day [route not stated]. After one month of vemurafenib initiation, she developed a keratotic papule on her right shoulder. A skin biopsy of the papule was performed, which ruled out the possibility of squamous cell carcinoma. Histologically, the lesion demonstrated mild papillomatous acanthosis and hyperkeratosis. Acantholysis and dyskeratosis with corp ronds and grains were noted. Therefore, the papule was diagnosed as ADA that developed due to the vemurafenib therapy [outcome not stated]. Author comment: "In conclusion, we experienced a case of vemurafenib-induced ADA." Komori T, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment. Journal of the European Academy of Dermatology and Venereology 31: e474-e475, No. 10, Oct 2017. Available from: URL: http:// doi.org/10.1111/jdv.14289 - Japan 803284154 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off